Studying how safe and effective deriphyllin is for treating breathing problems in real-life settings across multiple hospitals

Submission date 14/05/2025	Recruitment status Recruiting	Prospectively registered	
		[X] Protocol	
Registration date	Overall study status	Statistical analysis plan	
26/05/2025	Ongoing	[_] Results	
Last Edited 22/05/2025	Condition category Respiratory	Individual participant data	
		[X] Record updated in last year	

Plain English summary of protocol

Background and study aims

This study is looking at how safe and effective a medicine called Deriphyllin is for people with long-term breathing problems like asthma and chronic obstructive pulmonary disease (COPD). Deriphyllin is already used by many doctors because it helps open up the airways and reduce inflammation, but there isn't much information about how well it works in everyday medical settings. This study aims to fill that gap by collecting real-world data from patients across India.

Who can participate?

Adults aged 18 years or older who have been newly prescribed deriphyllin by their doctor as an extra treatment for asthma or COPD can take part. People who have used deriphyllin before, or who have certain health conditions like serious heart problems, seizures, severe liver disease, or stomach ulcers, cannot join. Pregnant or breastfeeding women are also not eligible.

What does the study involve?

Participants will continue their usual treatment as decided by their doctor - nothing will be changed or randomly assigned. Over a period of up to 3 months, they will have regular health checks. These include breathing tests, walking tests, blood tests, heart monitoring, and surveys about symptoms and satisfaction with treatment. Doctors will also keep track of any side effects.

What are the possible benefits and risks of participating?

Participants may benefit from close monitoring of their health during the study. Their involvement could also help improve treatment for others with similar breathing problems. The risks are minimal and mostly relate to known side effects of Deriphyllin, such as nausea, trouble sleeping, or heart-related symptoms.

Where is the study run from?

The study is being carried out at 200 clinics and hospitals across India. It is coordinated by a company called Tatvacare.

When is the study starting and how long is it expected to run for? The study will last for 6 months in total. This includes 3 months to enroll participants and up to 3 months of follow-up for each person.

Who is funding the study? The study is sponsored by Zydus Healthcare Limited, a pharmaceutical company based in Mumbai, India.

Who is the main contact? The main contact for the study is Dr. Kunal Jhaveri from Zydus Healthcare Limited. He can be reached by email at kunal.jhaveri@zyduslife.com

Contact information

Type(s) Principal Investigator

Contact name Dr Kunal Jhaveri

ORCID ID https://orcid.org/0009-0008-5582-9576

Contact details Zydus Tower CTS No- 460/6 of Village Pahadi Off I. B. Patel Road Goregaon (East) Mumbai India 400063 +91 (0)9601649741 Kunal.Jhaveri@zyduslife.com

Type(s) Public, Scientific

Contact name Dr Prachi Sharma

Contact details Digicare Healthcare Solutions Private Limited Ahmedabad India 380058 +91 (0)8290799906 patientsafety@tatvacare.in

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers PN/DERI0612/06

Study information

Scientific Title

Evaluating the safety and effectiveness of deriphyllin in respiratory disorders: a real-world multicentric study

Acronym

DERI-RWE

Study objectives

Deriphyllin, when used in routine clinical practice, is safe and effective in improving respiratory function and symptom control among patients with asthma, COPD, and other chronic respiratory conditions.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 22/04/2025, Central Independent Ethics Committee (Gini Aria, A 703, S No. 16/2/2A/1, Kondhwa Annex, Opposite Kjei Trinity College, Kondhwa Budruk, Pune, 411048, India; +91 9975167908; info@centraliec.com), ref: ECR/390/Indt/MH/2024

Study design

Observational prospective multi-centre study

Primary study design Observational

Secondary study design Registry

Study setting(s) Hospital

Study type(s) Safety, Efficacy

Participant information sheet No participant information sheet available

Health condition(s) or problem(s) studied

Chronic respiratory condition

Interventions

- Tab. Deriphyllin 300 mg SR
- Tab. Deriphyllin 450 mg SR
- Tab. Deriphyllin Retard 150 mg
- Tab. Deriphyllin Retard 300 mg

Participants enrolled in this real-world observational study will be adult patients (≥18 years) with chronic respiratory conditions such as asthma or COPD who are newly prescribed Deriphyllin by their treating physician. After providing informed consent, participants will undergo baseline assessments, including vital signs, respiratory function tests (spirometry, 6-minute walk test), symptom questionnaires (mMRC, CAT, ACT), ECG, and laboratory tests (CBC, liver enzymes, serum bilirubin, and creatinine).

Participants will be followed up over a period of 12 weeks (3 months). During this follow-up period, one or two additional visits will be conducted (Visit 1 and Visit 2, if applicable) to repeat clinical assessments and monitor for adverse events. At each follow-up visit, respiratory parameters, symptom control, ECG, laboratory tests, physician assessments, and patient satisfaction will be evaluated.

No investigational intervention is assigned by the study team; deriphyllin is prescribed as part of routine clinical care. Data collection is purely observational and non-interventional.

Total duration of observation per participant: 12 weeks Total duration of follow-up per participant: 12 weeks from enrolment

Intervention Type

Drug

Pharmaceutical study type(s)

Pharmacodynamic

Phase Not Applicable

Drug/device/biological/vaccine name(s) Deriphyllin

Primary outcome measure

Adverse events/serious adverse events (SAEs): description, severity, seriousness, outcome and causality, measured using investigator assessment and spontaneous patient reporting, continuously monitored from baseline through all study visits

Secondary outcome measures

Spirometry parameters: FEV1 (L), FEV1/FVC ratio (%), PEFR (L/min) measured using a calibrated spirometer at baseline to follow-up visits within 3 months of baseline
Distance walked (meters) in a standard 6-Minute Walk Test (6MWT) conducted per ATS guidelines at baseline to follow-up visits within 3 months of baseline
Symptom severity for COPD measured using mMRC dyspnea score (0–4) at baseline to follow-up visits within 3 months of baseline

4. COPD Assessment Test (CAT) at baseline to follow-up visits within 3 months of baseline

5. Asthma Control Test (ACT) at baseline to follow-up visits within 3 months of baseline 6. Clinician-assessed disease status (e.g., improved/stable/worsened) measured using Global Physician Assessment, investigator's clinical judgment recorded in CRF at Visit 1 (within 3 months), visit 2 (within 3 months, if any)

7. Subject satisfaction score (e.g., on a 5-point Likert scale) at Visit 1 (within 3 months), Visit 2 (within 3 months, if any)

8. Vital signs: oxygen saturation (%), blood pressure (mmHg), pulse rate (bpm) measured using pulse oximeter and automated blood pressure monitor at baseline to follow-up visits within 3 months of baseline

9. Laboratory parameters: CBC (Hb, WBC, platelets, etc), liver enzymes: ALT, AST, GGT (U/L), serum bilirubin (mg/dL), serum creatinine (mg/dL) measured using standard automated laboratory assays from venous blood samples at baseline to follow-up visits within 3 months of baseline

10. 12-lead ECG tracing and interpretation measured using a standard ECG machine at baseline to follow-up visits within 3 months of baseline

Overall study start date

22/04/2025

Completion date

31/05/2026

Eligibility

Key inclusion criteria

1. Patients aged >18 years of either gender

2. Patients with respiratory conditions such as asthma, COPD, and other conditions who are receiving deriphyllin treatment at the discretion of the treating physician

3. Patients for whom deriphyllin is being newly initiated as an add-on to ongoing therapy and who have not received deriphyllin treatment prior to study enrollment

Participant type(s)

Patient

Age group Adult

Lower age limit 18 Years

Sex Both

Target number of participants 4000

Key exclusion criteria

1. Patients under 18 years of age

2. Patients with known hypersensitivity to theophylline, etofylline, or any other components of

deriphyllin, or those using other methylxanthines (e.g., aminophylline)

3. Patients with significant cardiovascular conditions like arrhythmia, LVH with EF < 30%, and severe heart failure

4. Patients diagnosed with active peptic ulcers due to the potential exacerbation of

gastrointestinal symptoms

5. Patients having a history of epilepsy or other seizure disorders

6. Patients with severe liver dysfunction

7. Pregnant and lactating females

8. Any other conditions which are not suitable for Deriphyllin treatment at the discretion of the treating physician

Date of first enrolment 15/05/2025

Date of final enrolment 31/12/2025

Locations

Countries of recruitment India

Study participating centre Rehmania Nursing Home Bhiwandi India 421202

Study participating centre Dr Muddebihalkar Hospital Thane India 400601

Study participating centre G2 Clinics Mumbai India 421003

Study participating centre Bhanujyot Hospital Mumbai India 421306

Study participating centre Kapil Polyclinic Mumbai India 400013

Study participating centre Maniben Health Clinic Mumbai India 400028

Study participating centre Bhavesh Rameshchandra Shah Mumbai India 400008

Study participating centre Shivanand Manjunath Nayak Mumbai India 400004

Study participating centre Shivram Gopal Chitoor Mumbai India 400084

Study participating centre Neelam Hospital Mumbai India 400070 **Study participating centre Dr. James General Clinic** Mumbai India 400078

Study participating centre Sagar J Raiya Mumbai India 400080

Study participating centre Suma V Menon Sandor India 401202

Study participating centre Abhinandan Clinic Mumbai India 400067

Study participating centre DR. SAVLA DIABETIC & GENERAL CARE CLINIC Mumbai India 400067

Study participating centre Kinjal Modi Mumbai India 400092

Yashoda Clinic Mumbai India 400060

Study participating centre Dr Subhash Bendres Clinic Mumbai India 400058

Study participating centre Green Lung Clinic Mumbai India 400062

Study participating centre Ulhas G Shirodkar Mumbai India 400058

Study participating centre Sajwan Clinic Rasayani India 410207

Study participating centre Mhatre Clinic Alibag India 402201

Jaewale Hospital Osmanabad India 413501

Study participating centre Chavanda Hospital Latur India 413512

Study participating centre Vivekananda Hospital Latur India 413512

Study participating centre Vishal Ramesh More Pune India 411015

Study participating centre Shree Laxmi Hospital Pune India 411014

Study participating centre Dr. Pankaj Magar's Clinic Pune India 411038

Shanarayan Clinic Pune India 411035

Study participating centre Pawar Clinic Guhaghar India 415703

Study participating centre Shree Healthcare Ratnagiri India 415612

Study participating centre Cpr Hospital Kolhapur India 416004

Study participating centre Spruha Chest Clinic Kolhapur India 416004

Study participating centre Pankaj Multispeciality Sangli India 416416

Satyajieet V Borade Sangli India 416416

Study participating centre Rahul Rama Prabhudesai Margao India 403601

Study participating centre Shwas Respiratory Clinic Satara India 415001

Study participating centre Syed Tareque S Mhussain Nagpur India 440001

Study participating centre Christanand Hospital Brahmapuri India 441206

Study participating centre Dande Hospital Nagpur India 440010

Saoji Hospital Chikhali India 443201

Study participating centre Gungewad Chest Clinic Aurangabad India 431001

Study participating centre Niramaya Multispeciality Hospital Jalna India 431203

Study participating centre Apeksha Hospital Nanded India 431601

Study participating centre Gavasne Hospital Pune India 413102

Study participating centre Urney Hospital Beed India 431131

Kulkarni Hospital Sangamner India

422605

Study participating centre Matoshri Hospital And Critical Care Malegaon India 423202

Study participating centre Muktai Hospital Nashik India 422001

Study participating centre Sapphire Hospital Nashik India 422001

Study participating centre Lilawati Hospital Nashik India 422001

Study participating centre Parsh Chest Clinic Jalgaon India 425001

Hope Hospital Akola India 444001

Study participating centre Mohini Clinic & Day Care Centre Murtizapur India 444107

Study participating centre Vittal Hospital Washim India 444505

Study participating centre Gsl Medical College Rajahmundry India 533101

Study participating centre Jabbilli Hospital Rajahmundry India 533102

Study participating centre Delta Hospitals Rajahmundry India 533101

Sri Chaitanya Clinic Rajahmundry India 533102

Study participating centre Vel Clinic Madurai India 625001

Study participating centre Sri Ram Hospital Rajapalyam India 626117

Study participating centre Maddur Medical Centre Maddur India 571428

Study participating centre Ganesh Clinic Gonikopa India 571213

Study participating centre Navdurga Daycare Center Sardarsahar India 331403

Dr Sandeep Chest Clinic Sardarsahar India 331403

Study participating centre Dr Prabhat Clinic Jodhpur India 342001

Study participating centre Bairwa Chest Clinic Barmer India 344001

Study participating centre Tantia Hospital Sriganganagar India 335001

Study participating centre Abdul Qayyum Ansary Jhalawar India 326001

Study participating centre Goyal Chest & Tb Clinic Dholpur India 328001

Nr Meena Clinic Gangapur City

India 322201

Study participating centre Saini Chest Clinic Hindaun City India 322230

Study participating centre Navneet Clinic Udaipur India 313001

Study participating centre Dr Bera Chest & Tb Clinic Pali India 341001

Study participating centre Lalit Kumar Sharma Pali India 306401

Study participating centre Anil Kumar Kumawat Pali India 306401

Chawla Clinic Alwar India 301001

Study participating centre Vijay Tb Clinic Tonk India 304001

Study participating centre Chawda Clinic Indore India 452001

Study participating centre CHL Hospital Indore India 452001

Study participating centre Birla Hospital Indore India 452001

Study participating centre Dr Ujjawal Sharma Clinic Owalior India 474001

Dubey Nursing Home

Chhindwara India 480001

Study participating centre Dr Sunil Manohar Singh Prakash Medical Rewa India 486001

Study participating centre Dr Pandey Clinic Jabalpur India 482001

Study participating centre SMH Hospital Bhopal India 462025

Study participating centre Sai Hospital Bhopal India 462025

Study participating centre Rai Hospital Sagar India 470001

Shree Clinic Betul India 460001

Study participating centre Saarathi Lung Clinic Vadodara India 390007

Study participating centre Jagdish Clinic Vadodara India 390007

Study participating centre Dr. Ankur Rawal Hospital Khambhat India 388620

Study participating centre Nisarg Kishorkumar Oza Vadodara India 390009

Study participating centre Iris Hospital Anand India 388001

Madhuram Multispeciality Hospital Surat India 395009

Study participating centre Sadhna Kutir Hospital Kim India 394111

Study participating centre Haria L G Rotary Hospital Vapi India 396195

Study participating centre Rangsai Clinic Vyara India 394650

Study participating centre Bajrangdas Hospital Bhavnagar India 364001

Study participating centre Jivandeep Hospital Mahuva India 364290

Prajna Healthcare Ahmedabad

India 382424

Study participating centre Kishwa Hospital Modasa India 383315

Study participating centre Shivam Hospital Palanpur India 385001

Study participating centre Amrut Hospital Ahmedabad India 380015

Study participating centre Shivkrupa Clinic Radhanpur India 385340

Study participating centre Shaddha Clinic Radhanpur India 385340

Viral Multispeaciality Hospital Rajkot India 360001

Study participating centre Mmpj Hospital Bhuj India 370001

Study participating centre Divine Life Hospital Adipur India 370205

Study participating centre H. J. Doshi Hospital Rajkot India 370001

Study participating centre Prasad Health Care Bangalore India 560028

Study participating centre Geetha Clinic Bangalore India 560036

Sri Ganesh Clinic Bangalore India 560078

Study participating centre Sumathi Clinic Bangalore India 560062

Study participating centre United Medical Centre Bangalore India 560102

Study participating centre Sri Sai Sanjeevini Clinic Bangalore India 560102

Study participating centre Agara Chandrasekhar Raoshyam Bangalore India 560040

Study participating centre Baby Memorial Hospital Kerala India 670007

Wims Hospital Wayanad India 673577

Study participating centre Thoovakunnu Clinic Kannur India 670693

Study participating centre Mission Hospital Kannur India 670105

Study participating centre St. Johns Hospital Kottayam India 686014

Study participating centre Wellness Healthcare Ettumanoor India 686631

Study participating centre Sree Aanjaneya Diabetic And Medical Center Kaviyoor India 689582

Life Line Hospital Adoor India 691554

Study participating centre Vimala Hospital Kanjoor India 680575

Study participating centre M.a.j. Hospital Kochi India 682024

Study participating centre St. Joseph's Hospital Kothamangalam India 686691

Study participating centre Nirmala Medical Centre Muvattupuzha India 686661

Study participating centre Mother Care Hospital Palakkad India 678583

Karuna Medical College Palakkad India 678103

Study participating centre St James Hospital Thrissur India 680307

Study participating centre Neethi Clinic Thrissur India 680732

Study participating centre Vani Clinic Coimbatore 641002 India 641002

Study participating centre Chest Hospital Kozhikode India 673005

Study participating centre Alif Poly Clinic Malappuram India 679357

Study participating centre Map Clinic Salem India 636008

Study participating centre Ark Multispeciality Hospital Krishnagiri India 635001

Study participating centre M Sankarganesh Masilamani Shenbakkam India 632004

Study participating centre Jagannatham Clinic Tirupati India 517502

Study participating centre P.b Clinic Tirupati India 517561

Study participating centre Sri Venkataramana Cinic Tirupati India 517526

Study participating centre Nataraj Clinic Chittoor India 517001 **Study participating centre Venkayya Clinic** Bangarupalem India 517416

Study participating centre Susheella Clinic Palamaneru India 517408

Study participating centre Anandi Hospital Madanapalle India 517590

Study participating centre Ramesh Babu Clinic Tirupati India 517502

Study participating centre Sree Ras Clinic Tirupati India 517501

Study participating centre Desu Clinic Madanapalle India 517325

Rajiv Garg

Lucknow India 226003

Study participating centre Kedar Nath Poddar Kolkata India 700006

Study participating centre Apollo Multispeciality Hospitals Kolkata India 700054

Study participating centre Civil Hospital Rd Sangli India 416416

Study participating centre One Care Medical Center Coimbatore India 641044

Study participating centre Sun Medical And Research Center Thrissur India 680020

Parivar Hospital Gwalior India 474009

Study participating centre Saluja Chest Care Meerut India 250001

Study participating centre Navya Hospital Delhi India 110043

Study participating centre Apollo Clinic Valasaravakkam India 600087

Study participating centre P.sukumaran Kottayam India 686001

Study participating centre Modi Clinic- Excellence In Chest & Ent Pune India 411009

Health Harmony Mumbai India 400064

Study participating centre Shilpa Medical Research Centre Mumbai India 400068

Study participating centre Vora Clinic Mumbai India 400092

Study participating centre Om Clinic Mumbai India 400062

Sponsor information

Organisation Zydus Healthcare Ltd

Sponsor details Zydus Tower CTS No- 460/6 of Village Pahadi Off I. B. Patel Road Goregaon (East) Mumbai India 400063 +91 (0)9601649741 Kunal.Jhaveri@zyduslife.com

Sponsor type

Industry

Funder(s)

Funder type Industry

Funder Name Zydus Healthcare Ltd

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

Individual participant data (IPD) sharing plan

The data from this study is not expected to be made available. This decision is based on the proprietary nature of the research, as the study involves formulations and methods that are commercially sensitive and owned by the sponsor, Zydus Healthcare Limited.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol file</u>			20/05/2025	No	No